The Myogenesis Program Drives Clonal Selection and Drug Resistance in Rhabdomyosarcoma
A. G. Patel, X. Chen, X. Huang, M. R. Clay, N. Komarova, M. J. Krasin, A. Pappo, H. Tillman, B. A. Orr, J. McEvoy, B. Gordon, K. Blankenship, C. Reilly, X. Zhou, J. L. Norrie, , M. A. Dyer
This study shows that targeting developmental states in rhabdomyosarcoma can prevent disease recurrence by eliminating myoblast-like cells and inhibiting EGFR-dependent paraxial mesoderm populations.
bioRxiv · Jun 16, 2021Cancer Biology